Exact Sciences (EXAS) stock plummeted 7.25% in the pre-market trading session on Thursday, following multiple price target cuts from Wall Street analysts on concerns over the company's growth prospects.
Barclays analyst Luke Sergott lowered the firm's price target on EXAS to $65 from $70, while maintaining an Overweight rating on the stock. Sergott cited the company's Q4 results and guidance as factors behind the price target reduction. Similarly, BTIG cut its price target on the molecular diagnostics company to $65 from $75, but kept a Buy rating.
Additionally, Jefferies trimmed its price target on EXAS to $80 from $85 as part of its broader research roundup on U.S. companies. Despite the positive ratings from analysts, the price target cuts suggest a more cautious outlook on the stock's valuation and growth potential.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.